Bausch Health Companies Inc. (BHC) stock
BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3076% below fair value
$8.73+0.26 (+3.07%)
Close on Nov 18, 2026Market cap $3.27BP/E –Yield –
Bausch Health Companies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bausch Health Companies's operating income for the twelve months ending Sep 30, 2026 was $1.25B, down 34.3% year over year. For fiscal 2025 it was $1.81B, up 17.3% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $2.00B in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | +17.3% |
| FY2024 | Dec 31, 2024 | $1.55B | +60.5% |
| FY2023 | Dec 31, 2023 | $963.00M | +112.1% |
| FY2022 | Dec 31, 2022 | $454.00M | +0.9% |
| FY2021 | Dec 31, 2021 | $450.00M | -33.4% |
| FY2020 | Dec 31, 2020 | $676.00M | – |
| FY2019 | Dec 31, 2019 | -$203.00M | – |
| FY2018 | Dec 31, 2018 | -$2.38B | -2437.3% |
| FY2017 | Dec 31, 2017 | $102.00M | – |
| FY2016 | Dec 31, 2016 | -$566.00M | -137.1% |
| FY2015 | Dec 31, 2015 | $1.53B | -23.7% |
| FY2014 | Dec 31, 2014 | $2.00B | – |
| FY2013 | Dec 31, 2013 | -$409.50M | -613.8% |
| FY2012 | Dec 31, 2012 | $79.70M | -73.4% |
| FY2011 | Dec 31, 2011 | $299.96M | – |
| FY2010 | Dec 31, 2010 | -$110.09M | -160.8% |
| FY2009 | Dec 31, 2009 | $181.15M | +46.0% |
| FY2008 | Dec 31, 2008 | $124.11M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $983.00M | +58.8% |
| Q2 FY2026 | Jun 30, 2026 | $740.00M | +66.7% |
| Q1 FY2026 | Mar 31, 2026 | -$950.00M | -444.2% |
| Q4 FY2025 | Dec 31, 2025 | $474.00M | -15.1% |
| Q3 FY2025 | Sep 30, 2025 | $619.00M | +94.7% |
| Q2 FY2025 | Jun 30, 2025 | $444.00M | +14.1% |
| Q1 FY2025 | Mar 31, 2025 | $276.00M | -1.8% |
| Q4 FY2024 | Dec 31, 2024 | $558.00M | +54.1% |
| Q3 FY2024 | Sep 30, 2024 | $318.00M | +2171.4% |
| Q2 FY2024 | Jun 30, 2024 | $389.00M | -5.6% |
| Q1 FY2024 | Mar 31, 2024 | $281.00M | +60.6% |
| Q4 FY2023 | Dec 31, 2023 | $362.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $14.00M | -94.3% |
| Q2 FY2023 | Jun 30, 2023 | $412.00M | +155.9% |
| Q1 FY2023 | Mar 31, 2023 | $175.00M | -38.6% |
| Q4 FY2022 | Dec 31, 2022 | -$236.00M | -164.3% |
| Q3 FY2022 | Sep 30, 2022 | $244.00M | -57.5% |
| Q2 FY2022 | Jun 30, 2022 | $161.00M | – |
| Q1 FY2022 | Mar 31, 2022 | $285.00M | – |
| Q4 FY2021 | Dec 31, 2021 | $367.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $574.00M | +24.8% |
| Q2 FY2021 | Jun 30, 2021 | -$270.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$221.00M | -189.1% |
| Q4 FY2020 | Dec 31, 2020 | -$5.00M | – |
| Q3 FY2020 | Sep 30, 2020 | $460.00M | +39.8% |
| Q2 FY2020 | Jun 30, 2020 | -$27.00M | -110.5% |
| Q1 FY2020 | Mar 31, 2020 | $248.00M | -13.6% |
| Q4 FY2019 | Dec 31, 2019 | -$1.08B | -4404.0% |
| Q3 FY2019 | Sep 30, 2019 | $329.00M | +181.2% |
| Q2 FY2019 | Jun 30, 2019 | $257.00M | – |
| Q1 FY2019 | Mar 31, 2019 | $287.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $25.00M | – |
| Q3 FY2018 | Sep 30, 2018 | $117.00M | +207.9% |
| Q2 FY2018 | Jun 30, 2018 | -$245.00M | -240.0% |
| Q1 FY2018 | Mar 31, 2018 | -$2.28B | -1181.0% |
| Q4 FY2017 | Dec 31, 2017 | -$322.00M | -314.7% |
| Q3 FY2017 | Sep 30, 2017 | $38.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $175.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $211.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $150.00M | – |
See a number that looks wrong?